NovaBridge Executive Chairman Fu Wei Plans Open-Market Purchase of Up to $5M in Stock After Positive Trial Data

NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that Fu Wei, Executive Chairman of the Board, intends to purchase up to $5,000,000 of the Company's ADSs in open market transactions. The purchases started on January 15, 2026 and are ongoing as of the date of this press release. As the planned purchases are to be executed by Fu Wei via his controlled entity, NovaBridge cannot guarantee the number of ADSs to be purchased or the time frame in which the ADSs will be bought in the open market.

"2025 was a defining year for NovaBridge as we executed a new business strategy and built a truly global platform. This, combined with compelling Phase 1b dose expansion data for givastomig, reinforces our conviction in the strength of our clinical development capabilities, efficient execution, and long-term potential. We believe we are well-positioned for the next phase of growth, and I remain deeply confident in our team's ability to create meaningful value for patients and shareholders alike," said Fu Wei, Executive Chairman of NovaBridge and Chief Executive Officer of CBC Group.

NovaBridge recently announced positive givastomig dose expansion data from the Phase 1b combination study in patients with first line (1L) metastatic gastric cancer.